Subscribe to RSS
DOI: 10.1055/s-0042-1758353
Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma—Experience from an Indian Center
Funding There were no external sources of funding for this project.
Abstract
Anaplastic large cell lymphoma (ALCL) is the second most common type of peripheral T cell lymphoma and an aggressive mature T cell lymphoma. About 50 to 70% of systemic ALCLs are anaplastic lymphoma kinase positive (ALK +), the proportion even higher in the pediatric population. The 5-year survival after chemotherapy is around 70 to 80%. But there is a subgroup of ALK+ ALCL patients who are refractory to chemotherapy. Brentuximab vedotin is an approved agent for such patients. The activity of ALK inhibitors in ALK+ non-small cell lung cancer is well known and has been approved for use. The efficacy and safety of ALK inhibitors in ALK + ALCL are largely under-reported. Here we have reported our experience in the use of ALK inhibitors in relapsed refractory ALK+ ALCL.
Keywords
ALK+ ALCL - anaplastic large cell lymphoma - crizotinib in ALCL - ALK inhibitors in ALCL - relapsed refractory ALCL - targeted therapy in NHLPublication History
Article published online:
12 August 2023
© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Turner SD. An exploration into the origins and pathogenesis of anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK)-positive. Cancers (Basel) 2017; 9 (10) 141
- 2 Falini B, Martelli MP. Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica 2009; 94 (07) 897-900
- 3 Horwitz S, O'Connor OA, Pro B. et al; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019; 393 (10168): 229-240
- 4 Foster JH, Voss SD, Hall DC. et al. Activity of crizotinib in patients with ALK-aberrant relapsed/refractory neuroblastoma: a children's oncology group study (ADVL0912). Clin Cancer Res 2021; 27 (13) 3543-3548
- 5 Zhang XR, Chien PN, Nam SY, Heo CY. Anaplastic large cell lymphoma: molecular pathogenesis and treatment. Cancers (Basel) 2022; 14 (07) 1650 DOI: 10.3390/cancers14071650.
- 6 Mossé YP, Lim MS, Voss SD. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013; 14 (06) 472-480
- 7 Mossé YP, Voss SD, Lim MS. et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study. J Clin Oncol 2017; 35 (28) 3215-3221
- 8 Gambacorti Passerini C, Farina F, Stasia A. et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst 2014; 106 (02) djt378 DOI: 10.1093/jnci/djt378.
- 9 Sundara Rajan S, Dipak Amin A, Li L. et al. NPM1-ALK overexpression-driven toxicity in ALCL is partner dependent and mediated by STAT1 antagonism of STAT3 survival signaling, revealing a novel therapeutic strategy. Blood 2017; 130 (Suppl. 01) 2506 DOI: 10.1182/blood.V130.Suppl_1.2506.2506.